TFF Pharmaceuticals to Hold Fourth Quarter & Full-Year 2020 Financial Results & Bus. Results Conference Call on March 10, 2021
February 24 2021 - 8:30AM
Business Wire
Company conference call and webcast at 4:30 PM
ET
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative drug products based on its patented Thin Film Freezing
(TFF) technology platform, today announced that it will release its
financial results for the fourth quarter and full-year 2020 and
business update on Wednesday, March 10, 2021 at the close of the
U.S. financial markets.
Management will host a conference call to discuss the financial
results and provide an update on recent corporate and clinical
developments at 4:30 PM Eastern Time. A question-and-answer session
with investors will follow management’s remarks.
Conference Call Details:
Wednesday, March 10, 2021, 4:30 PM Eastern Time (ET)
Domestic Dial-In Number: Toll-Free: (877) 784-1702
International Dial-In Number (857) 770-0110
Conference ID: 9195779
Webcast Registration Link: https://edge.media-server.com/mmc/p/ev6cv5ub
Please access the Webcast Registration Link at least 15 minutes
ahead of the Conference to register, download, and install any
necessary audio software.
The conference call will also be available for replay for one
month on the Company's website, https://tffpharma.com, in the
Events Calendar of the Investors section.
About TFF Pharmaceuticals’ Thin Film Freezing technology
platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was
designed to improve the solubility and absorption of poorly
water-soluble drugs and is particularly suited to generate dry
powder particles with properties targeted for inhalation delivery,
especially to the deep lung, an area of extreme interest in
respiratory medicine. The TFF process results in a “Brittle Matrix
Particle,” which possesses low bulk density, high surface area, and
typically an amorphous morphology, allowing the particles to
supersaturate when contacting the target site, such as lung tissue.
Based upon laboratory experiments, the aerodynamic properties of
the particles are such that the portion of a drug deposited to the
deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative drug
products based on its patented Thin Film Freezing, or TFF,
technology platform. Early testing confirms that the TFF platform
can significantly improve the solubility and absorption of poorly
water-soluble drugs, a class of drugs that comprises approximately
one-third of the major pharmaceuticals worldwide, thereby improving
their pharmacokinetics. TFF Pharmaceuticals has two lead drug
candidates: Voriconazole Inhalation Powder and Tacrolimus
Inhalation Powder. The Company plans to add to this pipeline by
collaborating with large pharmaceutical partners. The TFF Platform
is protected by 42 patents issued or pending in the US and
internationally. To learn more about TFF Pharmaceuticals and its
product candidates, visit the Company’s website at
https://tffpharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210224005606/en/
Company Contacts: Glenn Mattes President and CEO TFF
Pharmaceuticals, Inc. gmattes@tffpharma.com 737-802-1973
Kirk Coleman Chief Financial Officer TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com 817-989-6358
Investor Relations and Media Contact: Paul Sagan
LaVoieHealthScience psagan@lavoiehealthscience.com 617-865-0041
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Aug 2024 to Sep 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Sep 2023 to Sep 2024